Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Jim Miller


Jim Miller Pharmtech contributing editor and EAB member

Jim Miller
President, PharmSource Information Services,
Bio/Pharmaceutical Outsourcing Report

PharmTech Contributing editor, Outsourcing Outlook

Jim Miller is the founder and president of PharmSource. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the pharmaceutical industry’s principal source of market intelligence on the business of contract research, development and manufacturing of bio/pharmaceuticals. PharmSource’s subscription databases, reports and consulting services are used by major pharmaceutical companies, contract manufacturers and contract research organizations to understand key market trends, identify new business opportunities and establish effective business and sourcing strategies. Jim writes regular columns on outsourcing for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm magazines.

Jim’s other career highlights include a stint as president and chief operating officer of St. Anthony Publishing, a pioneering provider of value-added information services to hospitals and physician practices. He was a consultant in corporate strategy with the Boston Consulting Group, a project economist for the World Bank, and a Peace Corps volunteer in Botswana. He holds an MBA degree from the Stanford University Graduate School of Business.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here